In light of the relatively high mutation rate of KIT in cutaneous melanoma and since BRAF, KIT, and NRAS mutations appear to be mutually exclusive, the screening of KIT mutations, at least in exons 9/11/13, is suggested in BRAF/NRAS double-wild-type melanoma patients (31, 34, 45, 46). This evidence concerns the gene NRAS and cutaneous melanoma.